Roche’s vamikibart shows 1-year vision gains in Phase 3 uveitic macular edema trials, offering a non-steroid alternative; see ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared ...

Even with good control of the underlying uveitis through systemic immunomodulatory therapy, uveitic macular edema often ...

Roche ( RHHBY ,RO.SW,ROG.SW) announced positive one-year results from its Phase III MEERKAT and SANDCAT studies evaluating investigational therapy vamikibart in adults with uveitic macular edema (UME) ...

Merck (MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, meeting the main goal of a late-stage clinical trial. However, patients receiving ...

Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections. Diabetic macular edema affects about 5% to 7% of people ...

The first patients have been enrolled in 4SIGHT, a global phase 3 trial comparing a single intravitreal injection of the investigational gene therapy 4D-150 with aflibercept 2 mg ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at ...